# OnCo record paper-asco-irae-guideline-jco-2021 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-asco-irae-guideline-jco-2021/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-asco-irae-guideline-jco-2021" ;
  schema:name "ASCO 2021 guideline: how to recognise and manage the immune-related side effects of checkpoint inhibitors"@en ;
  schema:description "The ASCO 2021 guideline is the consensus rulebook for checkpoint-inhibitor toxicity: grade the problem, hold or stop the drug, give steroids early, escalate to other immunosuppressants if they fail, and involve specialists."@en ;
  schema:url <https://onco.cc/key-papers/paper-asco-irae-guideline-jco-2021/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=Management%20of%20Immune-Related%20Adverse%20Events%20ASCO%20Guideline%20Update%20Schneider%20JCO%202021>, <https://www.asco.org/guidelines> ;
  schema:sameAs <https://doi.org/10.1200/JCO.21.01440> ;
  schema:datePublished "2021"^^xsd:gYear ;
  schema:author "Schneider BJ, Naidoo J, Santomasso BD, et al." ;
  onco:related <https://onco.cc/key-papers/paper-checkmate-067-10-year-nejm-2025/>, <https://onco.cc/key-papers/paper-hodi-ipilimumab-melanoma-nejm-2010/>, <https://onco.cc/technologies/cardio-oncology/> ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/ctla4/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/atezolizumab/> ;
  onco:institutions <https://onco.cc/institutions/asco/> ;
  onco:terms <https://onco.cc/terms/irae/>, <https://onco.cc/terms/crs/>, <https://onco.cc/terms/icans/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-toxicity-qol/>, <https://onco.cc/bottlenecks/b-knowledge-diffusion/>, <https://onco.cc/bottlenecks/b-care-fragmentation/> ;
  onco:journals <https://onco.cc/journals/jco/> .